article thumbnail

Palliative care beneficial to manage symptoms, improve quality of life for people with CVD

American Heart News - Heart News

Statement Highlights: Palliative medication management focuses on providing relief from symptoms and enhancing quality of life for people with cardiovascular disease throughout the various stages of the disease. Decisions about initiating, adjusting.

article thumbnail

Impact of IgAN on Quality of Life

HCPLive

Panelists discuss how IgA nephropathy affects patients’ quality of life, addressing both the physical symptoms and the emotional challenges associated with the condition.

article thumbnail

Hand Eczema Significantly Reduces Quality of Life

HCPLive

A meta-analysis shows hand eczema has a moderate-to-severe impact on quality of life and anxiety.

article thumbnail

Emotional Resilience Linked to Better Quality of Life for Those with Acne

HCPLive

This study pointed to the abilities of patients with acne to adapt to stress and adversity as helpful in making skin-related quality of life improvements.

article thumbnail

Study Examines Factors Impacting Health-Related Quality of Life in Male Patients with Gout

HCPLive

Various factors related to demographics, psychosocial behavior variables, and clinical characteristics were linked to health-related quality of life in patients with gout.

article thumbnail

Women with Little to No Migraine Disability Had a Lower Quality of Life Than Men

HCPLive

A study found that migraine-related disability worsens health-related quality of life, with gender-specific differences, particularly affecting women with mild disability.

article thumbnail

Sacubitril/valsartan is associated with improvements in quality of life in adult congenital heart disease patients with systemic right ventricular failure

Open Heart

Background Short-term improvements in quality of life (QOL) have been reported in adult congenital heart disease patients with systemic right ventricle (sRV) failure after treatment with sacubitril/valsartan. This study aimed to evaluate the medium-term QOL changes in sRV failure patients treated with sacubitril/valsartan.